Welcome to our dedicated page for Cosciens Biopharma news (Ticker: CSCI), a resource for investors and traders seeking the latest updates and insights on Cosciens Biopharma stock.
COSCIENS Biopharma Inc. (TSX: CSCI) generates news across natural active ingredients, nutraceutical concepts, cosmeceutical lines and pharmaceutical diagnostics. As a life sciences company focused on natural-based products, COSCIENS regularly issues updates on its portfolio of Avenanthramides and Beta Glucan active ingredients, macimorelin (Macrilen; Ghryvelin) diagnostic activities, and the use of its licensed Pressurized Gas eXpanded (PGX) Technology.
News coverage for CSCI commonly includes financial results and strategic updates, where COSCIENS reports on revenue trends, cost structure initiatives, restructuring efforts and zero-based budgeting programs. These releases often outline how the company is prioritizing its pipeline, refining operations and repositioning as a pure-play natural-based products life science company.
Investors and observers can also follow clinical and development milestones, such as Phase 1 and Phase 2a studies for Avenanthramides tablets as an anti-inflammatory product and progress in the AvenActive inflammation-related program. Announcements may detail trial design, safety findings and next-step evaluations.
COSCIENS’ news flow further covers product and technology developments in nutraceuticals, including Oat Beta Glucan chewable bar formulations and Yeast Beta Glucan products produced with PGX Technology, as well as updates on PGX unit construction and validation in Edmonton and Austria. In the pharmaceutical and diagnostic area, news items highlight commercialization steps and strategic assessments for Macrilen (macimorelin), along with distribution agreements in selected territories.
Corporate governance and capital markets developments, such as board reconstitution, leadership changes, voluntary delisting from the Nasdaq Capital Market and ongoing TSX listing and OTC trading arrangements, are also frequent topics. For anyone tracking CSCI news, this page offers a centralized view of COSCIENS’ operational, clinical, financial and strategic announcements over time.
COSCIENS Biopharma Inc. (NASDAQ: CSCI) reported its Q2 2024 financial results, highlighting a net loss of $1.4 million ($0.64 per share) compared to $0.9 million ($0.47 per share) in Q2 2023. The company ended the quarter with $27.8 million in cash. Total revenue increased to $2.3 million from $1.4 million in the same period last year, driven by higher sales of Avenanthramides, Oat Beta Glucan, and Oat Oil.
Operating expenses rose to $4.5 million from $1.9 million, primarily due to increased R&D costs and administrative expenses related to the recent Aeterna-Ceapro acquisition. The company expects to announce top-line data from its DETECT-trial evaluating macimorelin for childhood-onset growth hormone deficiency diagnosis in Q3 2024.